藤森 新 ふじもり しん 先生

来歴等

略歴

1976年 東京大学医学部 卒業
1980年 帝京大学医学部第二内科 助手
1988年 帝京大学医学部第二内科 講師
1990年 帝京大学医学部第二内科 助教授
1997年 帝京大学医学部内科 教授
2014年 帝京大学医学部附属病院 病院長
2016年 帝京大学医学部附属新宿クリニック 院長
2021年 帝京大学医学部附属新宿クリニック 院長 退職
2021年 両国東口クリニック 名誉院長（〜現在）

論文

• Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018 ;77(2):270-276.

  Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, Hidaka Y, Taniguchi A, Fujimori S, Yamamoto T.

• Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression. Sci Rep. 2018 ;8(1):11147.

  Takada T, Yamamoto T, Matsuo H, Tan JK, Ooyama K, Sakiyama M, Miyata H, Yamanashi Y, Toyoda Y, Higashino T, Nakayama A, Nakashima A, Shinomiya N, Ichida K, Ooyama H, Fujimori S, Suzuki H.

• GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2017 ;76(5):869-877.

  Nakayama A, Nakaoka H, Yamamoto K, Sakiyama M, Shaukat A, Toyoda Y, Okada Y, Kamatani Y, Nakamura T, Takada T, Inoue K, Yasujima T, Yuasa H, Shirahama Y, Nakashima H, Shimizu S, Higashino T, Kawamura Y, Ogata H, Kawaguchi M, Ohkawa Y, Danjoh I, Tokumasu A, Ooyama K, Ito T, Kondo T, Wakai K, Stiburkova B, Pavelka K, Stamp LK, Dalbeth N; Eurogout Consortium, Sakurai Y, Suzuki H, Hosoyamada M, Fujimori S, Yokoo T, Hosoya T, Inoue I, Takahashi A, Kubo M, Ooyama H, Shimizu T, Ichida K, Shinomiya N, Merriman TR, Matsuo H; Eurogout Consortium.

• Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open. 2017 Mar 29;7(3):e013425. doi: 10.1136/bmjopen-2016-013425.

  Kato A, Fujimaki Y, Fujimori S, Isogawa A, Onishi Y, Suzuki R, Yamauchi T, Ueki K, Kadowaki T, Hashimoto H.

• Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Res Care, 2016 Jan 5;4(1):e000156.doi:10.1136

  Kato A, Fujimaki Y, Fujimori S, Isogawa A, Onishi Y, Suzuki R, Yamauchi T, Ueki K, Kadowaki T, Hashimoto H.

• A qualitative study on the impact of internalized stigma on type 2 diabetes self-management. Patient Educ Couns. 2016 Jul;99(7):1233-1239. doi: 10.1016/j.pec.2016.02.002. Epub 2016 Feb 8.

  Kato A, Fujimaki Y, Fujimori S, Izumida Y, Suzuki R, Ueki K, Kadowaki T, Hashimoto H.

• Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci Rep. 2016 ;6:31003.

  Matsuo H, Tsunoda T, Ooyama K, Sakiyama M, Sogo T, Takada T, Nakashima A, Nakayama A, Kawaguchi M, Higashino T, Wakai K, Ooyama H, Hokari R, Suzuki H, Ichida K, Inui A, Fujimori S, Shinomiya N.

• Targeting uric acid and the inhibition of progression to end-stage renal disease. A propensity score analysis. PLoS One 2015 Dec 23;10(12):e0145506.doi:10.1371.

  Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Kaneko K, Shen ZY, Fujimori S.

• Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Mod Rheumatol 2015; 25(5): 779-83.

  Yamamoto T, Hidaka Y, Inaba M, Ishimura E, Ooyama H, Kakuta H, Moriwaki Y, Higami K, Ohtawara A, Hosoya T, Nishikawa H, Taniguchi A, Ueda T, Yamauchi T, Fujimori S, Mineo I, Yamanaka H.

• Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. Nucleosides Nucleotides Nucleic Acids, 2014:33(4-6):434-8.

  Oka Y, Tashiro H, Sirasaki R, Yamamoto T, Akiyama N, Kawasugi K, Shirafuji N, Fujimori S.

• Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 2014:18(6):876-84.

  Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S.

• Proteomic analysis to examine the role of matrix proteins in a gouty tophus from a patient with recurrent gout. Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):199-207.

  Kaneko K, Iwamoto H, Yasuda M, Inazawa K, Yamaoka N, Fukuuchi T, Tamura Y, Uchida S, Mawatari K, Nakagomi K, Yamada Y, Fujimori S.

• Hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiencies: HPRT1 mutations in new Japanese families and PRPP concentration. Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):218-22.

  Yamada Y, Nomura N, Yamada K, Kimura R, Fukushi D, Wakamatsu N, Matsuda Y, Yamauchi T, Ueda T, Hasegawa H, Nakamura M, Ichida K, Kaneko K, Fujimori S.

• Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011 :S50-6.

  Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

• An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011 :S44-9.

  Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

• Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. J Clin Rheumatol. 2011 :S35-43.

  Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

• An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011:S13-8.

  Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

• Molecular analysis of X-linked inborn errors of purine metabolism: HPRT1 and PRPS1 mutations. Nucleosides Nucleotides Nucleic Acids. 2011 ;30(12):1272-5.

  Yamada Y, Yamada K, Nomura N, Yamano A, Kimura R, Naiki M, Fukushi D, Wakamatsu N, Taniguchi A, Yamaoka N, Kaneko K, Fujimori S.

• Simultaneous determination of purine and pyrimidine metabolites in HPRT-deficient cell lines. Nucleosides Nucleotides Nucleic Acids. 2011; 30(12):1256-9.

  Yamaoka N, Inazawa K, Inagawa S, Yasuda M, Mawatari K, Nakagomi K, Fujimori S, Yamada Y, Kaneko K.

• Hypoxanthine guanine phosphoribosyltransferase (HPRT) mutations in the Asian population. Nucleosides Nucleotides Nucleic Acids. 2011 ;30(12):1248-55.

  Yamada Y, Wakamatsu N, Taniguchi A, Kaneko K, Fujimori S.

• Urinary stone analysis in a patient with hyperuricemia to determine the mechanism of stone formation. Nucleosides Nucleotides Nucleic Acids. 2011 ;30(12):1072-6.

  Kaneko K, Yoshida N, Okazaki K, Yamanobe T, Yamaoka N, Yasuda M, Ogata N, Yamada Y, Uchida S, Fujimori S.

• Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients. Nucleosides Nucleotides Nucleic Acids. 2011 ;30(12):1030-4.

  Fujimori S, Oka Y, Ogata N, Eto K.

• Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids. 2011 ;30(12):1035-8.

  Fujimori S, Ooyama K, Ooyama H, Moromizato H.

• Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010 ;29(4-6):321-4.

  Ogata N, Fujimori S, Oka Y, Kaneko K.

• Vascular endothelial growth factor acted as autocrine growth factor in an acute promyelocytic leukemia case. Leuk Lymphoma. 2010;51(4):717-9.

  Oka Y, Tashiro H, Shirasaki R, Sugao T, Nishi R, Akiyama N, Kawasugi K, Fujimori S, Shirafuji N.

• Successful unrelated bone marrow transplantation for a human immunodeficiency virus type-1-seropositive acute myelogenous leukemia patient following HAART. Int J Hematol. 2010 ;91(1):140-5.

  Oka Y, Tashiro H, Mizutani-Noguchi M, Koga I, Sugao T, Shirasaki R, Miura T, Akiyama N, Kawasugi K, Fujimori S, Shirafuji N.

著書

• 【監修】尿酸代謝異常.病気がみえる.代謝・内分泌疾患 第5版.メデイックメディア.2019

• 【分担執筆】痛風.今日の処方　改定第6版.南江堂.2019

• 【分担執筆】プリン・ピリミジン代謝異常-痛風と高尿酸血症.内科学書 第9版.中山書店.2019

• 【分担執筆】高尿酸血症・痛風の治療ガイドライン 第3版.日本痛風・核酸代謝学会編.診断と治療社.2018

• 【分担執筆】高尿酸血症・痛風.私の治療2017-2018年版.日本医事新報社.2017

• 【分担執筆】高尿酸血症・痛風.診療ガイドラインUP-TO-DATE 2016→2017.メディカルレビュー社.2016

• 【分担執筆】結晶誘発性関節炎.内科学　第10版.朝倉書店.2013

• 【分担執筆】プリン体代謝異常.カラー版　内科学.西村書店.2012

その他

• 【受賞】2005年　第7回　日本痛風・核酸代謝学会　学会賞